Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
LIGAND-DRUG CONJUGATE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/222019
Kind Code:
A1
Abstract:
Provided are a ligand-drug conjugate and use thereof. Specifically, provided are a ligand-drug conjugate represented by formula I or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

Inventors:
ZHU YI (CN)
WAN WEILI (CN)
ZHUO SHI (CN)
ZHU GUILI (CN)
YU TIANZI (CN)
Application Number:
PCT/CN2023/094714
Publication Date:
November 23, 2023
Filing Date:
May 17, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BAILI BIO CHENGDU PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K47/68; A61K39/00; A61P35/00; C07D401/00
Domestic Patent References:
WO2022022649A12022-02-03
WO2020132655A12020-06-25
Foreign References:
CN106132431A2016-11-16
CN110291097A2019-09-27
CN111601619A2020-08-28
US20210369705A12021-12-02
Other References:
CHEN TIANEN, TONGPENG SUPARAT, LU ZIYI, TOPATANA WIN, JUENGPANICH SARUN, LI SHIJIE, HU JIAHAO, CAO JIASHENG, LEE CHEESHIN, TIAN YI: "DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions", AGING AND CANCER, WILEY, vol. 3, no. 1, 1 March 2022 (2022-03-01), pages 44 - 67, XP093109780, ISSN: 2643-8909, DOI: 10.1002/aac2.12047
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: